SCHEMBL21147622

SCHEMBL21147622

Fc1cnc2[nH]c(C#Cc3ccc(C4CCN(c5ccccc5)CC4)cc3)cc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 4/20 0.53
VCP P55072 1/20 0.38
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 2/20 0.36
IP6K1 Q92551 1/20 0.35
DHFR P00374 1/20 0.34
ACACB O00763 1/20 0.34
MLYCD O95822 2/20 0.33
TLR8 Q9NR97 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
ALK Q9UM73 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
C1S P09871 1/20 0.33
NPC1 O15118 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20005047 0.96 SNCA (0.53) SNCAVCPALDH1A1HPGDHSD17B10
SCHEMBL22537543 0.85 SNCA (0.41) SNCAALDH1A1HPGDHSD17B10MAPT
SCHEMBL20004718 0.80 SNCA (0.60) SNCAMAPTALK
SCHEMBL20004447 0.79 SNCA (0.70) SNCAMAPT
SCHEMBL20005123 0.78 SNCA (0.56) SNCAVCPMAPTACACBALK
SCHEMBL20005066 0.77 SNCA (0.58) SNCAVCPALDH1A1MAPTALK
SCHEMBL20004511 0.76 SNCA (0.57) SNCAALDH1A1MAPTALK
SCHEMBL21115113 0.73 SNCA (0.55) SNCAMAPTALK
SCHEMBL20005086 0.71 SNCA (0.58) SNCAALDH1A1MAPT
SCHEMBL20005044 0.71 SNCA (0.55) SNCAALDH1A1MAPTACACBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10906900-B2 Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-02-02 US disclosed
US-20190211011-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10906900-B2 Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases PSEN2, CLN6, MAPT SNCA 4/4885VCP 489/4885ALDH1A1 1121/4885
US-20190211011-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES PSEN2, SNCA, MAPT SNCA 2/4885VCP 341/4885ALDH1A1 1382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.